Poly Medicure received a Rs 2.5 crore stamp duty demand from Delhi authorities. The company is challenging the order legally, citing jurisdictional issues and stating no material impact is expected.

Poly Medicure Challenges Rs 2.5 Crore Stamp Duty Order

Poly Medicure faces a ₹2.50 crore demand from the Government of NCT of Delhi regarding alleged deficit stamp duty payments on share allotments. The company is contesting the order legally, asserting it has already met its obligations and expects no material financial impact.

Reader Takeaway: Company challenges stamp duty demand; expects no material impact.

What just happened

The Office of the Divisional Commissioner, Government of NCT of Delhi, has issued an order demanding ₹2.50 crore (₹250.26 lakh) from Poly Medicure. This demand comprises ₹1.00 crore (₹100.26 lakh) for alleged deficit stamp duty and ₹1.50 crore (₹150.00 lakh) as a penalty. The authority claims stamp duty was payable under Article 19 of Schedule IA to the Indian Stamp Act, 1899, on share allotments made in 2021, 2022, and 2024, and that payments through depositories did not satisfy the liability in Delhi.

Why this matters

While the total demand is significant, Poly Medicure's management has stated that the order has jurisdictional and procedural flaws. The company believes it has already paid the applicable stamp duty. Crucially, the management explicitly stated that they do not expect a material impact on the company's financials or operations, indicating confidence in their legal standing.

The backstory

This dispute concerns stamp duty on share allotments made by Poly Medicure across several dates in 2021, 2022, and 2024. The Delhi government's authority believes the company did not meet its stamp duty obligations for these transactions under the Indian Stamp Act.

What changes now

Poly Medicure is pursuing legal action to challenge the order. The company is employing legal remedies to dispute the demand, which they deem non-maintainable. Investors will need to track the progress of this legal challenge.

Risks to watch

A key concern highlighted is the expansion of the scope of the final order. It included share allotments from August 2022, January 2024, March 2024, and August 2024, which were reportedly not specified in the initial show cause notices issued to the company.

Peer comparison

Stamp duty disputes can arise for companies involved in significant share issuances or transfers, particularly when operating across different state jurisdictions. The specifics of the Indian Stamp Act and state-specific interpretations are crucial.

Context metrics (time-bound)

The order pertains to share allotments made on various dates in 2021, 2022, and 2024. The specific demand and penalty figures are based on an order dated June 15, 2026.

What to track next

Investors should monitor future updates on the legal proceedings initiated by Poly Medicure. The company's ability to successfully challenge the order or any potential settlement will be key.